[go: up one dir, main page]

DK2983787T3 - Fremgangsmåde til behandling af posttraumatisk stresssygdom - Google Patents

Fremgangsmåde til behandling af posttraumatisk stresssygdom Download PDF

Info

Publication number
DK2983787T3
DK2983787T3 DK14783146.5T DK14783146T DK2983787T3 DK 2983787 T3 DK2983787 T3 DK 2983787T3 DK 14783146 T DK14783146 T DK 14783146T DK 2983787 T3 DK2983787 T3 DK 2983787T3
Authority
DK
Denmark
Prior art keywords
post
procedure
treatment
stress disorder
traumatic stress
Prior art date
Application number
DK14783146.5T
Other languages
English (en)
Inventor
Dennis S Charney
Adriana Feder
Original Assignee
Icahn School Med Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai filed Critical Icahn School Med Mount Sinai
Application granted granted Critical
Publication of DK2983787T3 publication Critical patent/DK2983787T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heat Treatment Of Articles (AREA)
  • Heat Treatment Of Strip Materials And Filament Materials (AREA)
DK14783146.5T 2013-04-12 2014-04-14 Fremgangsmåde til behandling af posttraumatisk stresssygdom DK2983787T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361811681P 2013-04-12 2013-04-12
US201361915947P 2013-12-13 2013-12-13
PCT/US2014/033997 WO2014169272A1 (en) 2013-04-12 2014-04-14 Method for treating post-traumatic stress disorder

Publications (1)

Publication Number Publication Date
DK2983787T3 true DK2983787T3 (da) 2020-01-06

Family

ID=51690056

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14783146.5T DK2983787T3 (da) 2013-04-12 2014-04-14 Fremgangsmåde til behandling af posttraumatisk stresssygdom

Country Status (14)

Country Link
US (4) US20160067196A1 (da)
EP (1) EP2983787B1 (da)
JP (1) JP6462663B2 (da)
KR (3) KR102424765B1 (da)
CN (2) CN112057441A (da)
AU (1) AU2014250756B2 (da)
CA (1) CA2909357C (da)
DK (1) DK2983787T3 (da)
ES (1) ES2760251T3 (da)
IL (1) IL242007B (da)
MX (1) MX370506B (da)
NZ (1) NZ713300A (da)
PL (1) PL2983787T3 (da)
WO (1) WO2014169272A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
CN112057441A (zh) 2013-04-12 2020-12-11 西奈山伊坎医学院 创伤后应激障碍的治疗方法
US9872841B2 (en) 2013-09-13 2018-01-23 National University Corporation Chiba University Application of R-ketamine and salt thereof as pharmaceuticals
MX2017001908A (es) 2014-08-13 2017-08-08 Janssen Pharmaceutica Nv Metodo para el tratamiento de la depresion.
MX2017003366A (es) 2014-09-15 2018-02-01 Janssen Pharmaceutica Nv Regimenes de dosificacion y métodos especificos para el tratamiento de la depresión con el genotipo val66met (snp rs6265).
EP3240422A1 (en) * 2014-12-31 2017-11-08 Icahn School of Medicine at Mount Sinai Method of maintaining the anti-depressant effect of ketamine with lithium
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) * 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
CA2987909C (en) 2015-06-27 2022-04-26 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
WO2017087691A1 (en) * 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
WO2017139382A1 (en) * 2016-02-08 2017-08-17 The Texas A&M University System Combination of adjuvant drugs esketamine and brimonidine for medical treatments
US11213494B2 (en) * 2016-03-24 2022-01-04 Case Western Reserve University Compositions and methods for the treatment of pervasive development disorders
US20180177744A1 (en) * 2016-12-22 2018-06-28 Gary Jay Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US12090123B2 (en) * 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
WO2019094757A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
KR20200113197A (ko) 2017-12-22 2020-10-06 얀센 파마슈티칼즈, 인코포레이티드 우울증 치료를 위한 에스케타민
CN118453559A (zh) 2018-02-15 2024-08-09 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
KR101880731B1 (ko) 2018-02-21 2018-07-20 주식회사 엠쓰리솔루션 외상 후 스트레스 극복용 컨텐츠 제공 시스템
CN112533595A (zh) 2018-05-04 2021-03-19 感知神经科学公司 治疗物质滥用的方法
IL278759B2 (en) 2018-06-27 2024-12-01 Clexio Biosciences Ltd A method for treating clinical depression
KR20210074275A (ko) 2018-10-05 2021-06-21 클렉시오 바이오사이언시스 리미티드 주요 우울 장애를 치료하기 위한 에스케타민의 복용 요법
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
JP2022541872A (ja) * 2019-05-31 2022-09-28 セロン ファーマ エス.アー. 医薬組成物の電子的に監督された非経口投与のための吸入器
WO2020252384A1 (en) * 2019-06-14 2020-12-17 Vorsanger Gary Treatment methods utilizing oxytocin receptor agonists
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
HUP1900358A1 (hu) 2019-10-12 2021-04-28 Meditop Gyogyszeripari Kft Lamotrigin és szertralin hatóanyag tartalmú gyógyszerkészítmények, ezek elõállítása és alkalmazása
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regime with esketamine for treating major depressive disorder
US20230157981A1 (en) * 2020-04-20 2023-05-25 Lobe Sciences Ltd. Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder
AU2021293178A1 (en) * 2020-06-17 2023-02-09 Lobe Sciences Ltd. Methods and compositions for treating mild traumatic brain injury, post-traumatic stress disorder and mild traumatic brain injury with post traumatic stress disorder
US11382873B1 (en) * 2021-01-08 2022-07-12 Vitalis Analgesics LLC Oral administration of ketamine
EP4329737A1 (en) * 2021-04-30 2024-03-06 Progressive Therapeutics Inc Ketamine and cannabis for the treatment of emotional disorders
TW202310825A (zh) * 2021-05-14 2023-03-16 美商西羅斯醫療公司 減少nmda受體拮抗劑之副作用
CN113967416A (zh) * 2021-10-29 2022-01-25 新疆医科大学第四附属医院 一种高浓度对氯苯丙氨酸的溶解方法及应用
KR20240117491A (ko) * 2023-01-25 2024-08-01 주식회사 아리바이오 포스포디에스테라제 타입 5 저해제를 유효성분으로 포함하는 외상 후 스트레스 장애의 예방 또는 치료용 조성물
WO2024192175A1 (en) * 2023-03-13 2024-09-19 Ultrasound AI, Inc. Artificial intelligence system for comprehensive medical diagnosis, prognosis, and treatment optimization through medical imaging

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH671155A5 (da) 1986-08-18 1989-08-15 Clinical Technologies Ass
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
EP2027854A1 (en) * 2002-11-18 2009-02-25 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
KR101406456B1 (ko) * 2005-04-06 2014-06-20 아다마스 파마슈티칼스, 인코포레이티드 Cns 장애의 치료를 위한 방법 및 조성물
EP2012762A4 (en) * 2006-03-22 2010-03-10 Sinai School Medicine INTRANASAL ADMINISTRATION OF KETAMINE FOR THE TREATMENT OF DEPRESSION
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
WO2008118785A2 (en) * 2007-03-23 2008-10-02 Tikvah Therapeutics Methods for treating depression using immediate-impact treatments and d-cycloserine
WO2008154337A1 (en) * 2007-06-08 2008-12-18 Healthpartners Research Foundation Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
US20100298305A1 (en) * 2008-11-26 2010-11-25 The United States Government, As Represented By The Department Of Veterans Affairs Tizanidine for the treatment of post-traumatic stress disorder and nightmares
EP2788356A4 (en) * 2011-12-09 2015-10-21 Demerx Inc SULFATESTER FROM NORIBOGAIN
EP2791352A1 (en) * 2011-12-14 2014-10-22 Astrazeneca AB Gabr-a2 diagnostic
US20130236573A1 (en) * 2012-03-12 2013-09-12 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
WO2014020155A1 (en) * 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
US20140057988A1 (en) 2012-08-23 2014-02-27 Stuart WEG Anxiolytic composition, formulation and method of use
CN112057441A (zh) 2013-04-12 2020-12-11 西奈山伊坎医学院 创伤后应激障碍的治疗方法

Also Published As

Publication number Publication date
PL2983787T3 (pl) 2020-04-30
EP2983787A1 (en) 2016-02-17
EP2983787A4 (en) 2017-01-18
KR20210050599A (ko) 2021-05-07
MX2015014385A (es) 2016-06-21
CN105377371A (zh) 2016-03-02
US20160067196A1 (en) 2016-03-10
IL242007B (en) 2020-08-31
JP2016516782A (ja) 2016-06-09
JP6462663B2 (ja) 2019-01-30
MX370506B (es) 2019-12-16
US20200147006A1 (en) 2020-05-14
NZ713300A (en) 2020-05-29
CA2909357A1 (en) 2014-10-16
WO2014169272A1 (en) 2014-10-16
US20160101069A1 (en) 2016-04-14
KR20150142012A (ko) 2015-12-21
ES2760251T3 (es) 2020-05-13
KR20220044380A (ko) 2022-04-07
KR102424765B1 (ko) 2022-07-22
US20230381118A1 (en) 2023-11-30
AU2014250756A1 (en) 2015-11-05
US10478405B2 (en) 2019-11-19
CN112057441A (zh) 2020-12-11
CA2909357C (en) 2022-02-22
AU2014250756B2 (en) 2019-03-07
EP2983787B1 (en) 2019-10-02
US11771661B2 (en) 2023-10-03

Similar Documents

Publication Publication Date Title
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK3035926T3 (da) Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
DK3076967T3 (da) Fremgangsmåder til behandling af residuelle symptomer på skizofreni
DK2968208T3 (da) Behandling af kataplexi
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK3043816T3 (da) Anti-b7-h1-antistoffer til behandling af tumorer
DK3851537T5 (da) Behandling af hyperbilirubinæmi
DK2954051T3 (da) Modificeret kapsid til genoverførsel til behandling af nethinden
DK3329884T3 (da) Implanterbar indretning til behandling af glaukom
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK2994159T3 (da) Forudsigelse af t-celleepitopers immunogenicitet
DK2964315T3 (da) System til behandling af neuromotorisk dysfunktion
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose
DK3076976T3 (da) Fremgangsmåder til behandling af cancer
DK2976359T4 (da) Fremgangsmåder til behandling af osteogenesis imperfecta
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3062811T3 (da) Angiopoietin-baserede interventioner til behandling af cerebral malaria
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3626270T3 (da) Behandling af kardiovaskulære sygdomme